The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy

Youqiong Ye, Yu Xiang, Fatma Muge Ozguc, Yoonjin Kim, Chun Jie Liu, Peter K. Park, Qingsong Hu, Lixia Diao, Yanyan Lou, Chunru Lin, An Yuan Guo, Bingying Zhou, Li Wang, Zheng Chen, Joseph S. Takahashi, Gordon B. Mills, Seung Hee Yoo, Leng Han

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Cancer chronotherapy, treatment at specific times during circadian rhythms, endeavors to optimize anti-tumor effects and to lower toxicity. However, comprehensive characterization of clock genes and their clinical relevance in cancer is lacking. We systematically characterized the alterations of clock genes across 32 cancer types by analyzing data from The Cancer Genome Atlas, Cancer Therapeutics Response Portal, and The Genomics of Drug Sensitivity in Cancer databases. Expression alterations of clock genes are associated with key oncogenic pathways, patient survival, tumor stage, and subtype in multiple cancer types. Correlations between expression of clock genes and of other genes in the genome were altered in cancerous versus normal tissues. We identified interactions between clock genes and clinically actionable genes by analyzing co-expression, protein-protein interaction, and chromatin immunoprecipitation sequencing data and also found that clock gene expression is correlated to anti-cancer drug sensitivity in cancer cell lines. Our study provides a comprehensive analysis of the circadian clock across different cancer types and highlights potential clinical utility of cancer chronotherapy. Ye et al. comprehensively analyzed alterations of clock genes and circadian rhythms across multiple human cancers and revealed strong interactions between clock genes and clinically actionable genes, which highlights the clinical utility of circadian timing in cancer chronotherapy.

Original languageEnglish (US)
JournalCell Systems
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Chronotherapy
Neoplasm Genes
Pharmacogenetics
Neoplasms
Genes
Circadian Rhythm
Genome
Gene Expression
Circadian Clocks
Atlases

Keywords

  • Cancer
  • Chronotherapy
  • Circadian rhythms
  • Clinical actionable genes
  • Clock genes
  • Drug
  • Pharmacogenomics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Cell Biology

Cite this

Ye, Y., Xiang, Y., Ozguc, F. M., Kim, Y., Liu, C. J., Park, P. K., ... Han, L. (Accepted/In press). The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy. Cell Systems. https://doi.org/10.1016/j.cels.2018.01.013

The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy. / Ye, Youqiong; Xiang, Yu; Ozguc, Fatma Muge; Kim, Yoonjin; Liu, Chun Jie; Park, Peter K.; Hu, Qingsong; Diao, Lixia; Lou, Yanyan; Lin, Chunru; Guo, An Yuan; Zhou, Bingying; Wang, Li; Chen, Zheng; Takahashi, Joseph S.; Mills, Gordon B.; Yoo, Seung Hee; Han, Leng.

In: Cell Systems, 01.01.2018.

Research output: Contribution to journalArticle

Ye, Y, Xiang, Y, Ozguc, FM, Kim, Y, Liu, CJ, Park, PK, Hu, Q, Diao, L, Lou, Y, Lin, C, Guo, AY, Zhou, B, Wang, L, Chen, Z, Takahashi, JS, Mills, GB, Yoo, SH & Han, L 2018, 'The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy', Cell Systems. https://doi.org/10.1016/j.cels.2018.01.013
Ye, Youqiong ; Xiang, Yu ; Ozguc, Fatma Muge ; Kim, Yoonjin ; Liu, Chun Jie ; Park, Peter K. ; Hu, Qingsong ; Diao, Lixia ; Lou, Yanyan ; Lin, Chunru ; Guo, An Yuan ; Zhou, Bingying ; Wang, Li ; Chen, Zheng ; Takahashi, Joseph S. ; Mills, Gordon B. ; Yoo, Seung Hee ; Han, Leng. / The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy. In: Cell Systems. 2018.
@article{dacc30f45ee94b31a4ac793ffead95b0,
title = "The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy",
abstract = "Cancer chronotherapy, treatment at specific times during circadian rhythms, endeavors to optimize anti-tumor effects and to lower toxicity. However, comprehensive characterization of clock genes and their clinical relevance in cancer is lacking. We systematically characterized the alterations of clock genes across 32 cancer types by analyzing data from The Cancer Genome Atlas, Cancer Therapeutics Response Portal, and The Genomics of Drug Sensitivity in Cancer databases. Expression alterations of clock genes are associated with key oncogenic pathways, patient survival, tumor stage, and subtype in multiple cancer types. Correlations between expression of clock genes and of other genes in the genome were altered in cancerous versus normal tissues. We identified interactions between clock genes and clinically actionable genes by analyzing co-expression, protein-protein interaction, and chromatin immunoprecipitation sequencing data and also found that clock gene expression is correlated to anti-cancer drug sensitivity in cancer cell lines. Our study provides a comprehensive analysis of the circadian clock across different cancer types and highlights potential clinical utility of cancer chronotherapy. Ye et al. comprehensively analyzed alterations of clock genes and circadian rhythms across multiple human cancers and revealed strong interactions between clock genes and clinically actionable genes, which highlights the clinical utility of circadian timing in cancer chronotherapy.",
keywords = "Cancer, Chronotherapy, Circadian rhythms, Clinical actionable genes, Clock genes, Drug, Pharmacogenomics",
author = "Youqiong Ye and Yu Xiang and Ozguc, {Fatma Muge} and Yoonjin Kim and Liu, {Chun Jie} and Park, {Peter K.} and Qingsong Hu and Lixia Diao and Yanyan Lou and Chunru Lin and Guo, {An Yuan} and Bingying Zhou and Li Wang and Zheng Chen and Takahashi, {Joseph S.} and Mills, {Gordon B.} and Yoo, {Seung Hee} and Leng Han",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.cels.2018.01.013",
language = "English (US)",
journal = "Cell Systems",
issn = "2405-4712",
publisher = "Cell Press",

}

TY - JOUR

T1 - The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy

AU - Ye, Youqiong

AU - Xiang, Yu

AU - Ozguc, Fatma Muge

AU - Kim, Yoonjin

AU - Liu, Chun Jie

AU - Park, Peter K.

AU - Hu, Qingsong

AU - Diao, Lixia

AU - Lou, Yanyan

AU - Lin, Chunru

AU - Guo, An Yuan

AU - Zhou, Bingying

AU - Wang, Li

AU - Chen, Zheng

AU - Takahashi, Joseph S.

AU - Mills, Gordon B.

AU - Yoo, Seung Hee

AU - Han, Leng

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Cancer chronotherapy, treatment at specific times during circadian rhythms, endeavors to optimize anti-tumor effects and to lower toxicity. However, comprehensive characterization of clock genes and their clinical relevance in cancer is lacking. We systematically characterized the alterations of clock genes across 32 cancer types by analyzing data from The Cancer Genome Atlas, Cancer Therapeutics Response Portal, and The Genomics of Drug Sensitivity in Cancer databases. Expression alterations of clock genes are associated with key oncogenic pathways, patient survival, tumor stage, and subtype in multiple cancer types. Correlations between expression of clock genes and of other genes in the genome were altered in cancerous versus normal tissues. We identified interactions between clock genes and clinically actionable genes by analyzing co-expression, protein-protein interaction, and chromatin immunoprecipitation sequencing data and also found that clock gene expression is correlated to anti-cancer drug sensitivity in cancer cell lines. Our study provides a comprehensive analysis of the circadian clock across different cancer types and highlights potential clinical utility of cancer chronotherapy. Ye et al. comprehensively analyzed alterations of clock genes and circadian rhythms across multiple human cancers and revealed strong interactions between clock genes and clinically actionable genes, which highlights the clinical utility of circadian timing in cancer chronotherapy.

AB - Cancer chronotherapy, treatment at specific times during circadian rhythms, endeavors to optimize anti-tumor effects and to lower toxicity. However, comprehensive characterization of clock genes and their clinical relevance in cancer is lacking. We systematically characterized the alterations of clock genes across 32 cancer types by analyzing data from The Cancer Genome Atlas, Cancer Therapeutics Response Portal, and The Genomics of Drug Sensitivity in Cancer databases. Expression alterations of clock genes are associated with key oncogenic pathways, patient survival, tumor stage, and subtype in multiple cancer types. Correlations between expression of clock genes and of other genes in the genome were altered in cancerous versus normal tissues. We identified interactions between clock genes and clinically actionable genes by analyzing co-expression, protein-protein interaction, and chromatin immunoprecipitation sequencing data and also found that clock gene expression is correlated to anti-cancer drug sensitivity in cancer cell lines. Our study provides a comprehensive analysis of the circadian clock across different cancer types and highlights potential clinical utility of cancer chronotherapy. Ye et al. comprehensively analyzed alterations of clock genes and circadian rhythms across multiple human cancers and revealed strong interactions between clock genes and clinically actionable genes, which highlights the clinical utility of circadian timing in cancer chronotherapy.

KW - Cancer

KW - Chronotherapy

KW - Circadian rhythms

KW - Clinical actionable genes

KW - Clock genes

KW - Drug

KW - Pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=85042918115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042918115&partnerID=8YFLogxK

U2 - 10.1016/j.cels.2018.01.013

DO - 10.1016/j.cels.2018.01.013

M3 - Article

C2 - 29525205

AN - SCOPUS:85042918115

JO - Cell Systems

JF - Cell Systems

SN - 2405-4712

ER -